![]() | |
Clinical data | |
---|---|
Other names | 19-Norspirolactone; 19-Nor-17α-(2-carboxyethyl)testosterone γ-lactone; 3-Oxo-17β-hydroxyestr-4-ene-17-propanoic acid lactone; 17-Hydroxy-3-oxo-19-Nor-17α-pregn-4-ene-21-carboxylic acid γ-lactone |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C21H28O3 |
Molar mass | 328.452 g·mol−1 |
3D model ( JSmol) | |
| |
|
SC-8109 is a steroidal antimineralocorticoid of the spirolactone group which was never marketed. [1] [2] It is a potent antagonist of the mineralocorticoid receptor and is more potent than the related drug SC-5233 (of which SC-8109 is the 19-nor analogue). [1] [3] However, SC-8109 was found to have relatively low oral bioavailability and potency, [1] [4] though it nonetheless produced a mild diuretic effect in patients with congestive heart failure. [2] Spironolactone (SC-9420; Aldactone), another spirolactone, followed and had both good oral bioavailability and potency, and was the first antimineralocorticoid to be marketed. [1] [5]
In addition to its antimineralocorticoid activity, SC-8109 shows potent progestogenic activity, with similar potency relative to that of progesterone. [6] Its analogue, SC-5233, possesses similar but less potent progestogenic activity. [6] In addition, SC-5233 has been assessed and found to possess some antiandrogenic activity, antagonizing the effects of testosterone in animals, and SC-8109 may as well. [7]
Compound | PR | AR | ER | GR | MR | SHBG | CBG |
---|---|---|---|---|---|---|---|
Progesterone | 100 | 3–10 | <1 | <1 | 3–10 | ? | ? |
SC-8109 | 191 | 25–50 | <1 | <1 | 15–25 | ? | ? |
Values are percentages (%). Reference ligands (100%) were progesterone for the PR , testosterone for the AR , estradiol for the ER , DEXA for the GR , and aldosterone for the MR . |
[SC-5233] (total dose of 5 mg/rat) partially blocked the effects of testosterone propionate on the seminal vesicles and prostate in similar animals.
![]() | |
Clinical data | |
---|---|
Other names | 19-Norspirolactone; 19-Nor-17α-(2-carboxyethyl)testosterone γ-lactone; 3-Oxo-17β-hydroxyestr-4-ene-17-propanoic acid lactone; 17-Hydroxy-3-oxo-19-Nor-17α-pregn-4-ene-21-carboxylic acid γ-lactone |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C21H28O3 |
Molar mass | 328.452 g·mol−1 |
3D model ( JSmol) | |
| |
|
SC-8109 is a steroidal antimineralocorticoid of the spirolactone group which was never marketed. [1] [2] It is a potent antagonist of the mineralocorticoid receptor and is more potent than the related drug SC-5233 (of which SC-8109 is the 19-nor analogue). [1] [3] However, SC-8109 was found to have relatively low oral bioavailability and potency, [1] [4] though it nonetheless produced a mild diuretic effect in patients with congestive heart failure. [2] Spironolactone (SC-9420; Aldactone), another spirolactone, followed and had both good oral bioavailability and potency, and was the first antimineralocorticoid to be marketed. [1] [5]
In addition to its antimineralocorticoid activity, SC-8109 shows potent progestogenic activity, with similar potency relative to that of progesterone. [6] Its analogue, SC-5233, possesses similar but less potent progestogenic activity. [6] In addition, SC-5233 has been assessed and found to possess some antiandrogenic activity, antagonizing the effects of testosterone in animals, and SC-8109 may as well. [7]
Compound | PR | AR | ER | GR | MR | SHBG | CBG |
---|---|---|---|---|---|---|---|
Progesterone | 100 | 3–10 | <1 | <1 | 3–10 | ? | ? |
SC-8109 | 191 | 25–50 | <1 | <1 | 15–25 | ? | ? |
Values are percentages (%). Reference ligands (100%) were progesterone for the PR , testosterone for the AR , estradiol for the ER , DEXA for the GR , and aldosterone for the MR . |
[SC-5233] (total dose of 5 mg/rat) partially blocked the effects of testosterone propionate on the seminal vesicles and prostate in similar animals.